Article By:
ChinaBio® Today
Saturday, March 9, 2024 2:20 PM EDT
Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors.